Pulmonary Sequelae at 4 Months After COVID-19 Infection: A Single-Centre Experience of a COVID Follow-Up Service.
COVID-19
Coronavirus
Pulmonary function tests
Pulmonary sequelae
Radiological fibrosis
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
10
05
2021
accepted:
17
06
2021
pubmed:
20
7
2021
medline:
11
8
2021
entrez:
19
7
2021
Statut:
ppublish
Résumé
At the end of the first year of the COVID-19 pandemic, more than 78 million known survivors were recorded. The long-term pulmonary sequelae of COVID-19 remain unknown. We performed a retrospective analysis of a post-COVID follow-up service to estimate the burden of persistent pulmonary morbidity in hospitalised COVID survivors. A total of 221 patients were followed-up: 44 intensive care unit (ICU) and 177 ward patients. Further investigations were planned as per British Thoracic Society Guidelines: For all ICU patients (n = 44) and for 38 of 177 (21%) ward-based patients who had persistent symptoms and/or persistent radiographic changes on CXR at their initial 8-week follow-up visit. In the ward-based cohort, statistically significant associations with persistent symptoms were being an ex- or current smoker, having pre-existing diabetes, and having a longer length of stay. In patients requiring further investigations, pulmonary function tests (PFTs; n = 67) at an average of 15 weeks post-discharge showed abnormalities in at least one PFT parameter in 79% (equating to 24% of the entire cohort). The most common abnormality was an abnormal diffusion capacity of carbon monoxide (TLCO), highest in the ICU cohort (64% ICU vs. 38% non-ICU). TLCO correlated negatively with length of stay and with maximum inspired FiO Our data add to the growing evidence that there will be pulmonary sequelae in a proportion of COVID survivors, providing some insight into what may become a significant chronic global health problem.
Identifiants
pubmed: 34278556
doi: 10.1007/s12325-021-01833-4
pii: 10.1007/s12325-021-01833-4
pmc: PMC8286847
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
4505-4519Informations de copyright
© 2021. The Author(s).
Références
Am J Case Rep. 2020 Nov 21;21:e926921
pubmed: 33219200
Clin Radiol. 2020 Jun;75(6):399-404
pubmed: 32321645
Crit Care. 2020 Jun 6;24(1):300
pubmed: 32505211
Eur Respir J. 2020 Aug 6;56(2):
pubmed: 32554533
J Infect. 2021 Jan;82(1):159-198
pubmed: 32473229
Complement Ther Clin Pract. 2020 May;39:101166
pubmed: 32379637
Clin Infect Dis. 2021 Sep 7;73(5):e1089-e1098
pubmed: 33220049
Infection. 2021 Feb;49(1):153-157
pubmed: 32725597
Thorax. 2021 Apr;76(4):402-404
pubmed: 33273023
Respir Res. 2020 Jun 29;21(1):163
pubmed: 32600344
Eur Respir J. 2021 Feb 25;57(2):
pubmed: 33479105
Ther Clin Risk Manag. 2020 Oct 29;16:1039-1046
pubmed: 33154646
Diabetes Res Clin Pract. 2020 Aug;166:108347
pubmed: 32711003
Respir Res. 2020 May 24;21(1):125
pubmed: 32448391
Indian J Radiol Imaging. 2017 Jul-Sep;27(3):342-349
pubmed: 29089687
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet Respir Med. 2021 Jul;9(7):763-772
pubmed: 33844996
Chest. 2005 Oct;128(4):2247-61
pubmed: 16236881
J Infect. 2020 Aug;81(2):e150-e152
pubmed: 32512021
Eur Respir J. 2021 Apr 29;57(4):
pubmed: 33303540
EClinicalMedicine. 2020 Aug;25:100463
pubmed: 32838236
Respir Med. 2021 Jan;176:106276
pubmed: 33278758
Respir Res. 2020 Oct 30;21(1):286
pubmed: 33126869
Respir Med. 2021 Jun;182:106421
pubmed: 33901788
Respir Med. 2020 Nov - Dec;174:106197
pubmed: 33120193
Respir Med. 2021 Jan;176:106272
pubmed: 33302142
J Korean Med Sci. 2020 Dec 07;35(47):e418
pubmed: 33289374
J Med Virol. 2021 Jan;93(1):257-261
pubmed: 32603481
Pulmonology. 2021 Jul-Aug;27(4):328-337
pubmed: 33262076
Obes Res Clin Pract. 2020 Jul - Aug;14(4):295-300
pubmed: 32660813
Eur Respir J. 2020 Jun 18;55(6):
pubmed: 32381497